Fosun Pharma extends guarantees for key subsidiaries, totaling 2.3 trillion yuan

Shanghai Fosun Pharmaceutical Group announced the extension of guarantees for several of its controlled subsidiaries, totaling approximately 2,337,703 million yuan as of October 15, 2025. This amount represents 49.46% of the group's net assets as of December 31, 2024. The guarantees are for various financing activities to support the operational needs of its subsidiaries.

Fosun Pharmaceutical Industrial received a 70,000 million yuan credit line from China Merchants Bank, while Fosun Health secured up to 15,000 million yuan from a trust bank and an additional 4,800 million yuan from Shanghai Rural Commercial Bank. Further guarantees include 15,700 million yuan for Xuzhou Star Morning Hospital from Pudong Development Bank, 10,000 million yuan for Fosun Antgene from Banco Tai Fung, and multiple guarantees for Jianjia Medical's various indirect subsidiaries, covering credit lines ranging from 770 million yuan to 1,100 million yuan from banks such as Hankou Bank, Bank of Communications, and Jiangxi Bank. All guarantees are within the scope of approvals from the 2024 annual shareholders' meeting, with no outstanding overdue guarantees reported.